Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC). This therapy is a radioactive medicine (Pluvicto) given into a vein. The main questions it aims to answer are: * Can scan results, radiation dose measurements, and blood test results predict which participants will have their prostate-specific antigen (PSA) level drop by half or more? * Can the same results predict how long participants live without their cancer getting worse? All participants receive Pluvicto as part of their regular medical care. Taking part in the study does not change their treatment. Participants will: * Receive up to 6 Pluvicto treatments, about every 6 weeks, as part of regular care * Have a PSMA PET/CT scan (an imaging test that shows where the cancer is) before treatment and after the last treatment, as part of regular care * Have 3 SPECT/CT scans after each treatment (at 3 to 4 hours, 24 hours, and 5 days) to measure how much radiation reached the tumors and organs, as part of regular care * Give 1 extra blood sample (10 ml) after each treatment to measure tumor DNA in the blood. It is taken from the same needle stick as routine blood tests. * Fill in a quality of life questionnaire (SF-36) before treatment and after every second treatment, during their hospital stay * Have check-ups every 4 to 6 months after treatment ends Researchers will also use existing medical records of people who started Pluvicto at the hospital before the study began.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie rak gruczołowy prostaty
- •Zaawansowany rak prostaty, który nie reaguje na leczenie hormonalne, wykazujący pozytywny wynik testu PSMA
- •Wcześniejsze leczenie inhibitorami ścieżki receptora androgenowego i chemioterapią na bazie taksan
- •Potwierdzenie pozytywności PSMA w badaniu PET/CT przed rozpoczęciem terapii
- •Wyrażenie świadomej zgody na uczestnictwo w badaniu (dla części prospektywnej)
✗ Disqualifies
- •Przeciwwskazania do terapii Pluvicto zgodnie z charakterystyką produktu
- •Brak zmian nowotworowych wykazujących pozytywność PSMA w badaniu PET/CT
- •Badanie diagnostyczne PSMA PET/CT nie wykonane odpowiednią metodą lub niedostępne do analizy
- •Inny aktywny nowotwór złośliwy (poza rakiem skóry bez cech melanomy), który mogłby wpłynąć na ocenę przeżycia
- •Odmowa uczestnictwa w badaniu lub brak podpisanej świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 14, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of Nuclear Medicine
Kaunas, Lithuania
Trial contact
Grytė Galnaitienė, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.